Researchers have uncovered a rare inherited mutation linked to prostate cancer—and it could help identify at-risk families ...

An AI-powered biomarker based on histology alone predicted survival among men with metastatic hormone-sensitive prostate cancer and identified those who benefitted from escalation to triplet therapy.

NeoGenomics, Inc. a annoncé le lancement du PTEN IHC CDx, le premier test de diagnostic compagnon par immunohistochimie approuvé par la Food and Drug Administration des États-Unis pour ...

Researchers at the University of British Columbia have identified a new form of hereditary prostate cancer that, while rare, ...

For Gary Buchanan, pickleball is more than a game; it's a place where, for a few hours, he can set aside the reality of ...

GE HealthCare et Mayo Clinic ont annoncé le lancement de la collaboration de recherche MI-BET , une étude théranostique novatrice conçue pour explorer une approche plus personnalisée de ...

Quand le corps envoie des signaux invisibles Beaucoup de personnes chez qui un cancer est diagnostiqué se souviennent d’une ...

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy ...

8.9% of patients on combo had little to no cancer at surgery vs 1% on hormone therapy alone Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We conducted a ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...